Dana-Farber Cancer Institute | Strategic Alliance Partners

Alice T. Shaw, MD, PhD, has been named Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute.

Alicia Morgans, MD, MPH, discusses enzalutamide plus radium-223 in with metastatic castration-resistant prostate cancer.

Dana-Farber Cancer Institute researchers have developed a blood test that could help transform the diagnosis and monitoring of multiple myeloma.

Narjust Florez, MD, discusses current treatment preferences in frontline IO for BRAF V600E–mutated metastatic non–small cell lung cancer.

Botensilimab plus balstilimab displayed durable responses in refractory CRC, including in heavily pretreated patient subsets.

Suzanne George, MD, discusses the evolving development of targeted therapies for patients with gastrointestinal stromal tumor.

The top 5 OncLive videos of the week cover insights in lung cancer, myelofibrosis, and mantle cell lymphoma.

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss ongoing research to watch in ovarian cancer.

Pasi A. Jänne, MD, PhD, discusses changes to the second-line treatment paradigm and treatment decision-making factors for patients with EGFR-mutated NSCLC.

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss data for neoadjuvant IMNN-001 plus chemotherapy in advanced epithelial ovarian cancer.

Treatment with casdatifan in combination with cabozantinib produced responses and was safe in patients with pretreated clear cell renal cell carcinoma.

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss data for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

Oncology experts share topline insights from 19 of the most exciting abstracts from the 2025 ASCO Annual Meeting.

Jade E. Jones, MD, discusses the importance of identifying the most effective first-line treatment regimen for PD-L1–positive TNBC.

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss data for radical up-front surgery in advanced ovarian cancer from the TRUST trial.

A study led by Dana-Farber Cancer Institute researchers found that chemoimmunotherapy before surgery for stage III NSCLC can help make surgery possible. 

Drs Morgans and Shore discuss the significance of the FDA approval of darolutamide plus ADT for metastatic castration-sensitive prostate cancer.

Dana-Farber researchers unveil insights into aggressive pediatric brain tumors, paving the way for targeted therapies and improved patient outcomes.

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss data for dostarlimab plus niraparib in advanced ovarian cancer.

Dr Dennis discusses guidelines for nasopharyngeal carcinoma management and data with first-line toripalimab plus chemotherapy in metastatic disease.

Daniel DeAngelo, MD, PhD, shares the rationale behind a meta analysis of asparaginase regimens vs hyper‐CVAD in adult and AYA patients with ALL.

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss how ADCs could continue to reshape ovarian cancer management.

A Dana-Farber study shows that an anti-inflammatory diet could extend overall survival after treatment for stage III colon cancer.

Sara M. Tolaney, MD, MPH, discusses data showing that T-DXd plus pertuzumab improved PFS vs SOC THP in first-line HER2-positive breast cancer.

Dr Mittendorf shares how ASCO plans to address the implications of federal research funding cuts and how structural reforms may bolster oncology progress.

Erica L. Mayer, MD, MPH, discusses the implications of data from the SERENA-6 trial for ESR1 testing in hormone receptor–positive breast cancer.

Sarah Sammons, MD, contextualizes the importance of T-DXd plus pertuzumab within the evolving ADC arsenal for HER2-positive breast cancer.

Elizabeth Mittendorf, MD, PhD, shares her ASCO priorities: expanding trial access, strengthening teams, and advancing global, evidence-based oncology care.

A PRO analysis showed that darolutamide plus ADT improved HRQOL outcomes vs placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.

Sara M. Tolaney, MD, MPH, shares interim efficacy results from the DESTINY-Breast09 study of first-line T-DXd plus pertuzumab in HER2-positive breast cancer.